The use of erythropoietin to increase red cell mass

Canadian Journal of Anesthesia

Volumn 50, Issue 6 SUPPL., 2003, Pages

  Goodnough, Lawrence T ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERRIC GLUCONATE; IRON; IRON DEXTRAN; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ALLOGRAFT; ANAPHYLAXIS; ANEMIA; BLEEDING; BLOOD; BLOOD AUTOTRANSFUSION; BLOOD BANK; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; ERYTHROCYTE TRANSFUSION; ERYTHROCYTE VOLUME; ERYTHROPOIESIS; HEART INFARCTION; HUMAN; HYPOTENSION; INFECTION RISK; IRON DEFICIENCY; KIDNEY FAILURE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RASH; REVIEW; SAFETY; SURGICAL TECHNIQUE; THORAX PAIN; THROMBOSIS; VIRUS TRANSMISSION;

ANEMIA; CRITICAL ILLNESS; ERYTHROCYTE TRANSFUSION; ERYTHROCYTE VOLUME; ERYTHROPOIETIN, RECOMBINANT; HUMANS;

EID: 0042536447     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine, part I: blood transfusion. N Engl J Med 1999; 340: 439-47.
2. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003; 361: 161-9.
3. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. JAMA 2000; 284: 229-35.
4. Finucane ML, Slovic P, Mertz CK. Public perception of the risk of blood transfusion. Transfusion 2000; 40: 1017-22.
5. Spahn DR, Casutt M. Eliminating blood transfusions. Anesthesiology 2000; 93: 242-55.
6. Hutchinson AB, Fergusson D, Graham ID, Laupacis A, Herrin J, Hillyer CD. Utilization of technologies to reduce allogeneic blood transfusion in the United States. Trans Med 2001; 11: 79-85.
7. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96: 823-33.
8. Goodnough LT, Verbrugge D, Marcus RE, Goldberg V. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell expansion. J Am Coll Surg 1994; 179: 171-6.
9. Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Clin Med 1995; 126: 57-64.
10. Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox Sang 1998; 75: 128-33.
11. Goodnough LT, Price TH, Parvin CA, et al. Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy. Br J Haem 1994; 87: 695-9.
12. Goodnough LT, Brittenham G. Limitations of the erythropoietic response to serial phlebotomy: implications for autologous blood donor programs. J Lab Clin Med 1990; 115: 28-35.
13. Goodnough LT, Price TH, Rudnick S. Soegiarso RW. Preoperative red blood cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion 1992; 32: 441-5.
14. Coleman PH, Stevens AR, Dodge HT, Finch CA. Rate of blood regeneration after blood loss. Arch Int Med 1953; 92: 341-8.
15. Crosby WH. Treatment of hemochromatosis by energetic phlebotomy. One patient's response to getting 55 liters of blood in 11 months. Br J Haematol 1958; 4: 82-8.
16. Goodnough LT, Merkel K. The use of parenteral iron and recombinant human erythropoietin therapy to stimulate erythropoiesis in patients undergoing repair of hip fracture. Int J Hematol 1996; 1: 163-6.
17. Finch CA. Erythropoiesis, erythropoietin, and iron. Blood 1982; 60: 1241-6.
18. Auerbach M, Barker L, Bahrain H, et al. Intravenous iron optimizes the response to erythropoietin in patients with anemia of cancer and cancer chemotherapy: results of a multicenter, open-label, randomized trial. Blood 2001; 98: 799a.
19. Muirhead M, Bargman J, Burgess E, et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 1995; 26: S1-S24.
20. Kaisi M, Ngwalle EWK, Runyoro DE, Rogers J. Evaluation and tolerance of response to iron dextran (Imferon) administered by total dose infusion to pregnant women with iron deficiency anemia. Int J Gynecol Obstet 1988; 26: 235-43.
21. Mays T, Mays T. Intravenous iron dextran therapy in the treatment of anemia occuring in surgical, gynecologic, and obstetric patients. Surg Gynecol Obstet 1976; 143: 381-4.
22. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243: 1726-31.
23. Woodman J, Shaw RJ, Shipman AJ, Edwards AM. A surveillance program on a long-established product: Imferon (Iron Dextran BP). Pharmaceut Med 1987; 1: 289.
24. Fishbane S, Ungureanu VD, Maeska JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 529-34.
25. Auerbach M, Winchester J, Wahab A, et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kid Dis 1998; 31: 81-6.
26. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextran. Am J Kid Dis 1999; 33: 464-70.
27. Sunder-Plassmann G, Horl WH. Safety aspects of parenteral iron in patients with end stage renal disease. Drug Saf 1997; 17: 241-50.
28. Silverberg DS, Blum M, Peer G, Kaplan E, Iaina A. Intravenous ferric saccharate as an iron supplementation in dialysis patients. Nephron 1996; 72: 413-7.
29. Sunder-Plassmann G, Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070-6.
30. Nissenson AR, Lindsay RM, Swan S, Sellgman P, Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Trial. Am J Kid Dis 1999; 33: 471-82.
31. Calvar C, Mata D, Alonso C, Ramos B, Lopez de Novales E. Intravenous administration of iron gluconate during haemodialysis. Nephrol Dial Transplant 1997; 12: 574-5.
32. Zanen AL, Adriaansen HJ, Van Bommel EFH, Posthuma R, Th. de Jong GM. "Over saturation" of transferrin after intravenous ferric glucomate (Ferrlecit) in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 820-4.
33. Seligman PA, Schleicher RB. Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 1999; 45: 898-901.
34. Pascual J, Teruel JL, Liano F, Sureda A, Ortuna J. Serious adverse reactions after intravenous ferric gluconate. Nephrol Dial Transplant 1992; 7: 271-2.
35. Hillman RS, Henderson PA. Control of marrow production by the level of iron supply. J Clin Invest 1969; 48: 454-60.
36. Henderson PA, Hillman RS. Characteristics of iron dextran utilization in man. Blood 1969; 34: 357-75.
37. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med 1997; 336: 933-8.
38. Corwin HL, Krantz SB. Anemia of the critically ill: "acute" anemia of chronic disease. Crit Care Med 2000; 28: 3098-9.
39. Hobisch-Hagen P, Wiederman F, Mayr A, et al. Blunted erythropoietin response to anemia in multiply traumatized patients. Crit Care Med 2001; 29: 743-7.
40. Von Ahsen N, Muller C, Serkes, Freiu, Eckardt KY. Important role of nondiagnostic blood loss and blunted erythropoietin response in the anemia of intensive care patients. Crit Care Med 1999; 27: 2630-9.
41. Van Iperen CE, Gaillard CAJM, Kraaijenhagen RJ, Braam BG, Marx JJM, van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000; 28: 2773-8.
42. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients. JAMA 2002; 288: 2827-35.
43. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of endstage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-8.
44. Muirhead N. Recombinant human erythropoietin (epoietin alpha) in anemic patients on hemodialysis: Canada. In: Erslev AJ (Ed.). Erythropoietin. Baltimore (MD): Johns Hopkins University Press; 1991: 241-68.
45. Kaupke CJ, Butler GC, Vaziri ND. Effect of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol 1993; 10: 1672-9.
46. Taylor JE, Henderson IS, Stewart WK, et al. Erythropoietin and spontaneous platelet aggregation in heamodialysis patients. Lancet 1991; 338: 1361-2.
47. Taylor JE, Belch JJF, McLaren M, et al. Effect of erythropoietin therapy and blood withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. Kidney Int 1993; 44: 182-90.
48. Gordge MP, Leaker B, Patel A, et al. Recombinant human erythropoietin shortens the uremic bleeding time without causing intravascular haemostatic activation. Thromb Res 1990; 57: 171-82.
49. Vigano G, Benigni A, Mendogni P, et al. Recombinant human erythropoietin to correct uremic bleeding. Am J Kidney Dis 1991; 1: 44-9.
50. Raine AE. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications for erythropoietin therapy. Lancet 1988; I: 97-100.
51. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoietin. N Engl J Med 1998; 339: 584-90.
52. Goodnough LT, Rudick S, Price TH, et al. Increased collection of autologous blood preoperatively with recombinant human erythropoietin therapy. N Engl J Med 1989; 321: 1163-8.
53. Goodnough LT, Price TH, EPO Study Group. A phase III trial of recombinant human erythropoietin in non-anemic orthopaedic patients subjected to aggressive autologous blood phlebotomy: dose, response, toxicity, and efficacy. Transfusion 1994; 34: 66-71.
54. Price TH, Goodnough LT, Voyler W, et al. The effect of recombinant erythropoietin therapy administration on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial. Transfusion 1996; 36: 29-36.
55. Goodnough LT, Monk TG. Evolving concepts in autologous blood procurement: case reports, of perisurgical anemia complicated by myocardial infarction. Am J Med 1996; 101: 33S-7S.
56. Biesma DH, Bronkhorst PJH, de Groot PG, et al. The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and bloood rheology in autologous blood donors. J Lab Clin Med 1994; 124: 42-7.
57. Sowade O, Ziemer S, Sowade B, et al. The effect of preoperative recombinant human erythropoietin therapy on platelets and hemostasis in patients undergoing cardiac surgery. J Lab Clin Med 1997; 129: 376-83.
58. Sowade O, Warnke H, Scigalla P, et al. Avoidance of allogeneic blood transfusions by treatment with epooetin beta (recombinant human erythropoietin) in patients undergoing open heart surgery. Blood 1997; 89: 411-8.
59. Sowade O, Gross J, Sowade B, et al. Evaluation of oxygen availability with oxygen status algorithm in patients undergoing open heart surgery treated with epoetin beta. J Lab Clin Med 1997; 129: 97-105.
60. D'Ambra MN, Gray RJ, Hillman R, et al. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg 1997; 64: 1686-93.
61. Goodnough LT, Despotis GJ, Parvin CA. Erythropoietin therapy in patients undergoing cardiac operations. Ann Thorac Surg 1997; 64: 1579-80.
62. Goodnough LT, Spence R, Shander A. Bloodless medicine; clinical care without allogeneic blood transfusion. Transfusion 2003; 43: 668-76.
63. Monk TG, Goodnough LT, Brecher ME, et al. A prospective, randomized trial of three blood conservation strategies for radical prostatectomy. Anesthesiology 1999; 91: 24-33.
64. Kaisi M, Ngwalle EWK, Runyoro DE, Rogers J. Evaluation of tolerance of and response to iron dextran administered by total dose infusion to pregnant women with iron deficiency anemia. Int J Gynecol Obstet 1988; 26: 235-43.
65. Anand S, Nissenson AR. Pure red cell aplasia: an emerging epidemic in dialysis patients? Perit Dial Int (in press).
66. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-75.
67. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346: 1584-6.
68. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci 2000; 97: 10526-31.
69. Brezden CB, Phillips KA, Abdodell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18: 2695-701.
70. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84(Suppl 1): 3-10.
71. Glaspy J, Jadeja JS, Justice G, et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 2001; 84(Suppl 1): 17-23.
72. Smith RE, Jaiyesimi LA, Meza LA, et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 2001; 84(Suppl 1): 24-30